Shares of Scholar Rock Holding ( SRRK 13.36%) are soaring today, up 13.7% as of 1:14 p.m. ET. The move comes as the S&P 500 ...

Shares of Scholar Rock (SRRK) soared 16% on Wednesday after the company announced that its investigational drug Apitegromab, ...

Scholar Rock (Nasdaq: SRRK) has unveiled encouraging Phase II data for its experimental therapy apitegromab, showing the drug ...

Shares of Scholar Rock Holdings (SRRK) jumped nearly 15% in intraday trading Wednesday after the biopharmaceutical firm reported positive results from a weight-loss drug trial. The Cambridge, ...

Scholar Rock’s investigational spinal muscular atrophy drug helped patients taking Eli Lilly’s obesity blockbuster Zepbound ...

While the results were an important proof point for so-called anti-myostatin drugs, Scholar Rock executives indicated the ...

Scholar Rock said its investigational therapy helped preserve lean mass among patients taking a powerful weight loss drug.

In combination with Eli Lilly’s tirzepatide, marketed as Zepbound for obesity, Scholar Rock’s monolonal antibody helped ...

Shares of Scholar Rock climbed after the company disclosed what it called positive results from a Phase 2 study assessing its drug for weight loss. Shares rose 12% to $35.01 in pre-market trading ...

Investing.com -- Scholar Rock Holding Corp (NASDAQ: SRRK) stock surged 16.4% after the company announced positive results from its Phase 2 EMBRAZE trial evaluating apitegromab in combination with ...

Scholar Rock said on Wednesday its experimental drug helped overweight patients preserve lean mass in a mid-stage trial when used in combination with Eli Lilly's weight-loss treatment.

Scholar Rock Holding Corporation's lead candidate, apitegromab, has shown promising efficacy in treating SMA and is awaiting FDA and EMA approval, with a potential market launch by late 2025.